Medivation and Pfizer Announce Results from Phase 3 Concert Trial of Dimebon
- Details
- Category: Pfizer
Medivation, Inc. (NASDAQ: MDVN) and Pfizer Inc. (NYSE: PFE) today announced results from the CONCERT trial, which is a Phase 3 trial that evaluated dimebon (latrepirdine) when added to ongoing treatment with donepezil HCL tablets in patients with mild-to-moderate Alzheimer's disease.
Novartis to restructure US business to strengthen competitive position
- Details
- Category: Novartis
Novartis Pharmaceuticals plans to strengthen its long-term competitive position in anticipation of the Diovan® (valsartan) patent expiration and an expected reduction in demand for Rasilez®/Tekturna® (aliskiren) following termination of the ALTITUDE clinical study.
AstraZeneca and IMS Health announce real-world evidence collaboration in Europe
- Details
- Category: AstraZeneca
AstraZeneca has entered into a three-year collaboration agreement with IMS Health, the leading provider of information, services and technology for the healthcare sector, to advance the use of real-world evidence based on observational and retrospective studies throughout Europe to inform the delivery of effective and cost-efficient healthcare.
A New Resource That Offers Personalized Nutritional Guidance to Achieve Better Health
- Details
- Category: Pfizer
Millions of resolutions come with every New Year, many of which are to get healthy. But, there's a lot of confusion around what constitutes healthy nutrition, which is a key piece of the puzzle.
Bayer HealthCare to Share Lab Space with Start-Up Companies
- Details
- Category: Bayer
One year after the opening of its U.S. Innovation Center, Bayer HealthCare is expanding its U.S. research model. The company will open the CoLaborator™ - a 550 square meter shared lab for start-up life science companies whose technology platforms, drug targets or drug candidates align with Bayer's portfolio.
AstraZeneca reaffirms December 2011 financial guidance for 2011
- Details
- Category: AstraZeneca
During a routine consensus collection process, confidential Company information was inadvertently embedded in a spreadsheet template sent to the sell-side analyst community that follows the Company.
Bristol-Myers Squibb to Acquire Inhibitex
- Details
- Category: Bristol-Myers Squibb
Bristol-Myers Squibb Company (NYSE:BMY) and Inhibitex, Inc. (Nasdaq:INHX) have signed a definitive agreement under which Bristol-Myers Squibb will acquire Inhibitex for $26.00 per share in cash pursuant to a cash tender offer and second step merger.
More Pharma News ...
- Pfizer Receives FDA Approval to Extend Use of Prevnar 13®
- Boehringer Ingelheim significantly expands its supply center for China
- First-of-its-kind endovascular trial of the investigational Esprit(TM) therapy
- GlaxoSmithKline provides update on divestment of non-core over-the-counter (OTC) brands
- AstraZeneca updates on olaparib and TC-5214 development programmes
- Four potential blockbusters in the Pharma pipeline
- Amgen and Watson Announce Collaboration to Develop and Commercialize Oncology Biosimilars